Algert Global LLC Has $3.03 Million Holdings in STAAR Surgical (NASDAQ:STAA)

Algert Global LLC decreased its position in shares of STAAR Surgical (NASDAQ:STAA) by 30.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 81,528 shares of the medical instruments supplier’s stock after selling 35,127 shares during the period. Algert Global LLC owned about 0.17% of STAAR Surgical worth $3,029,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of STAA. Mutual of America Capital Management LLC raised its holdings in shares of STAAR Surgical by 214.7% in the second quarter. Mutual of America Capital Management LLC now owns 26,459 shares of the medical instruments supplier’s stock valued at $1,260,000 after buying an additional 18,051 shares during the last quarter. ClariVest Asset Management LLC bought a new position in shares of STAAR Surgical in the second quarter worth about $1,223,000. Granite Investment Partners LLC acquired a new position in shares of STAAR Surgical during the second quarter worth approximately $17,237,000. Cetera Investment Advisers bought a new stake in shares of STAAR Surgical during the second quarter valued at approximately $1,135,000. Finally, Kayne Anderson Rudnick Investment Management LLC grew its stake in shares of STAAR Surgical by 50.1% during the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 592,621 shares of the medical instruments supplier’s stock valued at $28,215,000 after purchasing an additional 197,717 shares during the last quarter. Institutional investors own 96.70% of the company’s stock.

STAAR Surgical Stock Down 1.7 %

NASDAQ:STAA opened at $28.06 on Wednesday. The stock’s fifty day simple moving average is $30.82 and its 200-day simple moving average is $36.47. The firm has a market capitalization of $1.38 billion, a P/E ratio of 63.39 and a beta of 0.61. STAAR Surgical has a 12-month low of $25.88 and a 12-month high of $52.68.

Analyst Upgrades and Downgrades

STAA has been the topic of several research reports. Stifel Nicolaus reduced their price objective on STAAR Surgical from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Monday, August 26th. Canaccord Genuity Group cut their price target on STAAR Surgical from $41.00 to $31.00 and set a “hold” rating on the stock in a research note on Friday, November 1st. Finally, Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Thursday, October 31st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $43.33.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.